Submitted by barrons9707 in business
BofA upgraded shares of biotech Gilead to Buy from Neutral, and lifted the target price to $95 from $88.
Submitted by barrons9707 in business
BofA upgraded shares of biotech Gilead to Buy from Neutral, and lifted the target price to $95 from $88.